

No difference in sensitivity between males (triangles) and females (plusses), so the data can be pooled for the derivation of the CED.

A problem is the choice of the CES. Is 20% critical?

Monte Carlo for AFtot for EXA

Assessment factor	Distribution	Geometric mean	Geometric standard deviation
AF_1: interspecies, kinetics	discrete value	4	-
interspecies, residual	lognormal	1	6
AF_2: intraspecies	discrete value	10	-
AF_3: duration of exposure semi-chronic to chronic	lognormal	2	4



GM = 80
GSD = 9.6
P87 = 1000
P95 = 3300

rivm

This slide shows the probabilistic combination of (distributions of) assessment factors

CED-human for EXA



P5 = 0.25 mg.kg^{-1}bw.d^{-1}
AFtot relative to NOAEL is 1600

rivm

Conclusions and recommendations

- Long-term goal: probabilistic RA?

- Stepwise-implementation
  - Investigate further distributions of AFs
  - Investigate further probabilistic benchmark procedure
  - Investigate further probabilistic exposure assessment
  - Communication with risk managers

- Further research:
  - Interspecies extrapolation need further analysis of variability in toxicokinetics (scaling) and pharmacodynamics
  - Intraspecies: research into human variability
  - Refinement of extrapolation for study period
  - CES-derivation



No difference in sensitivity between males (triangles) and females (plusses), so the data can be pooled for the derivation of the CED.

A problem is the choice of the CES. Is 20% critical?

Monte Carlo for AFtot for EXA

Assessment factor	Distribution	Geometric mean	Geometric standard deviation
AF_1: interspecies, kinetics	discrete value	4	-
interspecies, residual	lognormal	1	6
AF_2: intraspecies	discrete value	10	-
AF_3: duration of exposure semi-chronic to chronic	lognormal	2	4



GM = 80
GSD = 9.6
P87 = 1000
P95 = 3300

rivm

This slide shows the probabilistic combination of (distributions of) assessment factors

CED-human for EXA



P5 = 0.25 mg.kg^{-1}bw.d^{-1}
AFtot relative to NOAEL is 1600

rivm

Conclusions and recommendations

- Long-term goal: probabilistic RA?

- Stepwise-implementation
  - Investigate further distributions of AFs
  - Investigate further probabilistic benchmark procedure
  - Investigate further probabilistic exposure assessment
  - Communication with risk managers

- Further research:
  - Interspecies extrapolation need further analysis of variability in toxicokinetics (scaling) and pharmacodynamics
  - Intraspecies: research into human variability
  - Refinement of extrapolation for study period
  - CES-derivation